A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
CIBINQO™ Pregnancy Registry: An Observational Study of the Safety of Abrocitinib Exposure in Pregnant Women and Their Offspring
Sponsor: PPD Development, LP
A observational or N/A phase clinical study on Atopic Dermatitis, this trial is actively recruiting participants. The trial is conducted by PPD Development, LP and has accumulated 16 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
16 versions recorded-
Jan 2026 — Present [monthly]
Recruiting
-
Dec 2025 — Jan 2026 [monthly]
Recruiting
-
Oct 2025 — Dec 2025 [monthly]
Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Recruiting
▶ Show 11 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Recruiting
-
Jun 2025 — Jul 2025 [monthly]
Recruiting
-
Apr 2025 — Jun 2025 [monthly]
Recruiting
-
Oct 2024 — Apr 2025 [monthly]
Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Sep 2023 — Jul 2024 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jul 2023 — Sep 2023 [monthly]
Not Yet Recruiting
-
May 2023 — Jul 2023 [monthly]
Not Yet Recruiting
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- PPD Development, LP
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .